JP2005068060A - Pharmaceutical composition containing lactoferrin and method for producing processed food containing lactoferrin - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a material capable of potentiating the efficacy of other medicinal ingredients used in alternative medicine. <P>SOLUTION: An enteric preparation as a pharmaceutical composition is provided. This enteric preparation is obtained by incorporating an appropriate amount of lactoferrin in a combination of various active ingredients for alternative medicine, whose efficacies have been confirmed for morbid conditions respectively. This enteric preparation is highly effective in potentiating their efficacies. <P>COPYRIGHT: (C)2005,JPO&NCIPI

Description

  The present invention relates to a pharmaceutical composition containing lactoferrin optimized for treatment of various pathological conditions and a method for producing processed foods.

  The term lactoferrin in the present invention refers to both mammalian lactoferrin and genetically modified lactoferrin produced by genetically recombining a mammalian lactoferrin gene into a microorganism and culturing the recombinant microorganism. Lactoferrin is known as a protein exhibiting antibacterial activity and immunostimulatory action and is generally considered to be a milk-specific protein because it is contained in mammalian milk. However, it is not surprisingly known that it is widely distributed in the living body. That is, lactoferrin is contained in tears, saliva, pancreatic juice, bile, and other secretions, and covers the surface of the mucous membrane in contact with the outside world. Furthermore, 5 μg of lactoferrin is included per million neutrophils, and the human body produces 5 g of lactoferrin every day when calculated from the half-life of neutrophils. The fact that lactoferrin and its receptors are distributed in a wide range of organs and organs suggests that lactoferrin has a wide variety of functions. However, research on the function of lactoferrin has just started and there is no research progress to be seen.

  In the previous patent application, the present inventor has not only exhibited antibacterial action and immunostimulatory action as previously described, but also (1) serum cholesterol lowering action, and (2) basal metabolic elevation factor <energy metabolism. Newly discovered to show the action of regulating>, (3) action to block pain, (4) action to relieve pain occurring at the joint of bone and bone such as arthritis, that is, <act on the central nervous system> Applied. Lactoferrin has traditionally been anti-allergic, anti-metastatic, anti-angiogenic, therapeutic for viral hepatitis, therapeutic for peptic ulcer, therapeutic for gastritis caused by Helicobacter pylori infection, and treatment for skin-infected mycosis It has been known to exhibit effects due to immune activation such as effects, an effect of enhancing the action of antibiotics on a mouse sepsis model. However, the energy metabolism regulation and central effects of lactoferrin were completely new discoveries.

  Furthermore, the present inventor has studied ingredients that enhance the action by ingesting together with lactoferrin for each disease state for many years. Active ingredients of alternative medicine that can be used in combination with lactoferrin are not known unexpectedly. For example, ingredients that have a synergistic or additive effect with lactoferrin for the pathological conditions exemplified in paragraph [0003] include β-lactam antibiotics, egg white Not known except by lysozyme. In addition, only examples are known in which lactoferrin utilizes the property of forming a strong complex compound with heavy metal ions, and the chromium complex is applied to the treatment of diabetes.

  When the present inventor administered a lactoferrin enteric preparation to a patient volunteer and examined the usefulness by collecting the clinical results, the pathological conditions in which lactoferrin was effective were as follows. Arthritis, allergies, anemia, Alzheimer's disease and decreased memory, bronchitis, cancer, hypercholesterolemia and arteriosclerosis, chronic fatigue syndrome, constipation, depression, cold, atopic dermatitis and other skin diseases and eczema, hypertension Inflammatory bowel disease, diabetes, liver disease, stomatitis, tooth decay and periodontal disease, urinary tract infection and sinusitis and other chronic infections, obesity and peptic ulcers. In other words, it was revealed that lactoferrin has a therapeutic effect on a wide range of disease states.

  In general, lactoferrin has been found to be highly safe. For example, lactoferrin extracted from milk is greater than 5 grams per kg body weight, which is the physical limit at which acute toxicity to rats and beagle dogs can be administered orally. Furthermore, no abnormal findings were observed after oral administration of up to 2 g / kg lactoferrin to rats and beagle dogs for 13 weeks. Milk lactoferrin is a component of milk protein, and addition to infant formulas for raising infants and infants that require careful nutritional attention is also recognized. As shown in paragraph [0005], lactoferrin exhibits therapeutic effects in many intractable diseases that are difficult to treat and follow a chronic course. However, it may be said that almost no synergistic or additive therapeutic effects with other medicinal ingredients used in alternative medicine in combination with lactoferrin have been attempted so far.

  In order to enhance the pathological condition improving effect of lactoferrin, the present inventors examined the combined effect with various medicinal ingredients used in alternative medicine for patients with a pathological condition showing the improving effect. The pathological conditions for which the combined effect was examined are as follows. Arthritis, that is, rheumatoid arthritis, painful diseases of the bone joint including osteoarthritis, allergic diseases including atopy and asthma, anemia, Alzheimer's disease and decreased memory, bronchitis, malignant lymphoma Skin cancer and eczema such as solid cancer, hypercholesterolemia and arteriosclerosis, chronic fatigue syndrome, constipation, depression, cold, atopic dermatitis, hypertension, inflammatory bowel disease, liver disease and viral hepatitis, stomatitis Oral ulcers, tooth decay and periodontal disease, urinary tract infections, chronic infections such as sinusitis, obesity and peptic ulcers.

  Rheumatoid arthritis, osteoarthritis and the like are major factors for the onset and deterioration of angiogenesis in the joint. Orally administered lactoferrin greatly increases intestinal interleukin-18 production and is therefore expected to inhibit angiogenesis in joints. Therefore, even if used alone, it alleviates pain in these pathological conditions. For patients with rheumatoid arthritis, osteoarthritis, low back pain, forty shoulders, joint pain due to sports, etc., the medicinal ingredients that synergistically or additively relieve local pain when combined with lactoferrin are as follows It was as follows. Ω-3 essential fatty acids such as vitamin C, vitamin E, folic acid, vitamin D, organic inorganic calcium salt, glucosamine sulfate, chondroitin sulfate, hyaluronic acid, fucoidan, γ-linolenic acid, eicosapentadecanoic acid, docosahexaenoic acid , Pepper extract or capsaicin, ginger extract and so on. That is, when lactoferrin and one or more selected from the above-mentioned medicinal ingredients are administered in combination, the therapeutic effect of lactoferrin is significantly improved.

  Lactoferrin also has a significant therapeutic effect on bronchial asthma, rhinitis, urticaria, atopic dermatitis and the like that are associated with immune abnormalities. The medicinal ingredients of alternative medicine that enhance the therapeutic effect when used in combination with lactoferrin were as follows. Vitamin C, γ-linolenic acid, eicosapentadecanoic acid, omega-3 essential fatty acids such as docosahexaenoic acid, flavonoids, glycyrrhizin, licorice extract and so on. When one or more selected from these are administered simultaneously, the therapeutic effect of lactoferrin on allergy is significantly enhanced.

  Since lactoferrin inhibits angiogenesis, it has the effect of strongly suppressing metastasis of malignant tumors and eliminating cancer metastasis. On the other hand, lactoferrin relieves cancer pain that affects 70-80% of end-stage cancer patients, and has the effect of calming the anxiety of patients who threaten the fear of death. When orally administered to cancer patients in combination with lactoferrin, the medicinal ingredients showing the combined effect are calcium salt, folic acid, selenium, vitamin C, vitamin E, carotenoids, isoflavones, lactic acid bacteria and bifidobacteria, grape seed extract, Green tea extract, inositol-hexaphosphate, peptidoglycan and glycan extracted from basidiomycetes, royal jelly made by bees, propolis, fucoidan extracted from seaweed, and so on. When one or more selected from the above active ingredients are mixed or formulated with lactoferrin, the efficacy is improved synergistically or additively.

  Table 1 below shows alternative medicine components that synergistically or additively enhance the therapeutic effects when mixed or formulated with lactoferrin. By using one or more alternative medical ingredients in Table 1 in combination with lactoferrin, the effectiveness of lactoferrin can be enhanced synergistically or additively.

The present inventor has completed the following inventions (1) to (20) based on the above findings.
(1) Lactoferrin and vitamin C, vitamin E, folic acid, vitamin D, organic and inorganic calcium salts, glucosamine sulfate, chondroitin sulfate, γ-linolenic acid, eicosapentadecanoic acid, docosahexaenoic acid, etc. A novel pharmaceutical composition for treating arthritis, comprising one or more selected from fatty acids, colostrum powder, protein concentrate of colostrum powder, chili extract or capsaicin, ginger extract and the like, and processed food.
(2) Containing one or more selected from lactoferrin and vitamin C, omega-3 essential fatty acids such as γ-linolenic acid, eicosapentadecanoic acid, docosahexaenoic acid, flavonoids, glycyrrhizin and licorice extract A novel pharmaceutical composition for treating allergy and processed food, characterized in that
(3) A novel pharmaceutical composition for treating anemia and a processed food comprising one or more selected from lactoferrin and vitamin B ₁₂ , iron agents such as folic acid, iron gluconate, and heme iron.
(4) A novel Alzheimer's disease characterized by containing one or more selected from lactoferrin and vitamin B ₁₂ , vitamin E, L-carnitine, phosphatidylserine, vinpocetine, ginkgo biloba extract and the like Pharmaceutical compositions for treating memory impairment and processed foods.
(5) A novel pharmaceutical composition for bronchitis treatment and processed food comprising lactoferrin and a zinc compound such as zinc gluconate.
(6) Lactoferrin and calcium, folic acid, selenium, vitamin C, vitamin E, carotenoids, isoflavones, lactic acid bacteria and bifidobacteria, grape seed extract, green tea extract, inositol-hexaphosphate, peptidoglycan extracted from basidiomycetes And one or more selected from glycans, propolis, and the like, and a novel pharmaceutical composition for treating cancer and processed food.
(7) lactoferrin and nicotinic acid, vitamin B ₆ vitamin B ₁₂ , vitamin E, folic acid, koji mold, γ-linolenic acid, eicosapentadecanoic acid, omega-3 fatty acids such as docosahexaenoic acid, plant sterol, green tea and its Extract: A novel hypercholesterolemia and arteriosclerotic medicament characterized by containing one or more selected from grape seed extract, garlic and its extract, lysozyme, lactalbumin, whey protein, etc. Compositions as well as processed foods.
(8) It is characterized by containing one or more selected from lactoferrin and vitamin B group complex, magnesium salt, calcium salt, carnitine, coenzyme Q ₁₀ , sorghum extract, ginseng and its extract, etc. A novel pharmaceutical composition for treating chronic fatigue syndrome and processed food.
(9) A novel pharmaceutical composition for the treatment of constipation and processed food, comprising one or more selected from lactoferrin, kelp, senna and extracts thereof.
(10) A novel pharmaceutical composition for treating depression, comprising one or more selected from lactoferrin and vitamin B group complex, phenylalanine, S-adenosylmethionine, ginkgo biloba extract and the like, and processed food.
(11) A novel medicine for treating colds, comprising one or more selected from lactoferrin, vitamin C, zinc compounds such as zinc gluconate, vitamin A, egg white lysozyme, garlic and extracts thereof Compositions as well as processed foods.
(12) Contains lactoferrin and fish oil, linseed oil and ω-3 fatty acids such as γ-linolenic acid, eicosapentadecanoic acid, docosahexaenoic acid, quercetin, grape seed extract, ginkgo biloba extract, glycyrrhizin A novel dermatitis and eczema pharmaceutical composition and processed food comprising one or more selected from licorice extract and the like.
(13) Lactoferrin and calcium salt, potassium salt, vitamin C, vitamin E, fish oil, linseed oil and ω-3 fatty acids such as γ-linolenic acid, eicosapentadecanoic acid, docosahexaenoic acid, garlic and the like A novel pharmaceutical composition for hypertension treatment and processed food, comprising one or more selected from extracts and the like.
(14) selected from lactoferrin and zinc compounds such as folic acid and zinc gluconate, lactic acid bacteria and bifidobacteria, γ-linolenic acid, eicosapentadecanoic acid, docosahexaenoic acid and other essential ω-3 fatty acids, licorice extract and the like A novel pharmaceutical composition for treating inflammatory bowel disease and processed food, characterized by containing one or more.
(15) A novel pharmaceutical composition for treatment of liver disease and processing, comprising one or more selected from lactoferrin and vitamin B group complex, coenzyme Q ₁₀ , digestive enzymes, licorice extract and the like Food.
(16) A novel pharmaceutical composition for treating stomatitis, characterized in that it contains one or two or more selected from lactoferrin selected from vitamin B complex, vitamin C, zinc compounds such as zinc gluconate, licorice extract and the like. As well as processed foods.
(17) immunoglobulins concentrate of lactoferrin and bovine colostrum and bovine colostrum, egg white lysozyme, calcium salts, vitamin D, vitamin C, fluorine compounds, flavonoids, containing one or two or more selected from coenzyme Q _10, etc. A novel dental caries and pharmaceutical composition for periodontal disease treatment and processed food.
(18) A novel pharmaceutical composition for treating urinary tract infections, comprising one or more selected from lactoferrin and vitamin C, bovine colostrum, bovine colostrum immunoglobulin concentrate, and cranberry extract And processed foods.
(19) A novel obesity characterized by containing one or more selected from lactoferrin and chromium compounds, pepper tincture, capsaicin, raspberry alcoholic extract, carnitine, 5-hydroxytryptamine, konjac and glucomannan. Pharmaceutical compositions for treatment as well as processed foods.
(20) A novel peptic ulcer treatment characterized by containing one or more selected from lactoferrin and vitamin C, iron agents such as iron gluconate, lactic acid bacteria and bifidobacteria, licorice and extracts thereof Pharmaceutical compositions as well as processed foods.

  One embodiment of the present invention is a preparation in which the surface of a lactoferrin granule or tablet is coated with an enteric film that does not dissolve in the stomach but dissolves in the intestine. More specifically, it is as follows.

  The milk-derived lactoferrin lyophilized powder has a very small specific gravity per unit volume and is a light and fine powder, so that it is difficult to directly compress into tablets. Further, since 10% or more of water coexists or is unstable under conditions of high temperature and high humidity, it is desirable to formulate in a dry state. Therefore, lactoferrin and medicinal ingredients of alternative medicine are mixed with a disintegrant, and the mixture is compressed with a slag machine and compressed to form a thin large flat disk, which is crushed and filtered to produce granules of a certain size. Align. The granules can be covered with an enteric coating, and a certain amount can be filled into hard capsules to produce a product. In the case of commercialization as a tablet, the tablet can be covered with an enteric film and then commercialized after a lubricant is added to the granule and tableted.

  Excipients used in producing the enteric preparation of the present invention include monosaccharides or disaccharides such as lactose, sucrose, and glucose, sugar alcohols such as sorbitol and xylitol, and starches such as corn starch and potato starch. Crystalline cellulose and inorganic substances include light silica gel, synthetic aluminum silicate, magnesium aluminate metasilicate, and calcium hydrogen phosphate. Examples of the binder include starches, carboxymethyl cellulose (CMC), hydroxypropyl cellulose (HPC), carboxymethyl cellulose-sodium salt, and polyvinylpyrrolidone. Examples of disintegrants used for the purpose of disintegrating them into primary particles in the lower gastrointestinal tract include starch, carboxymethylcellulose-sodium salt, carboxymethylcellulose-calcium salt, croscarmellose sodium, and carboxymethylstarch sodium. . Examples of coating agents for enteric coating of tablets and granules include hydroxypropylmethylcellulose phthalate, carboxymethylethylcellulose, cellulose acetate phthalate, methacrylic acid copolymer, and shellac that dissolves in an alkaline region. is there.

  The formulation of the present invention is generally about 0.1 mg to about 100,000 mg, preferably about 1 mg to about 50,000 mg, more preferably about 10 mg to about 10,000 mg per day as lactoferrin. Appropriate amounts of the active ingredients used in can be administered at once or in portions to a patient in need of treatment or improvement of condition with the formulations of the invention. The dosage can be individually determined according to the age, weight and purpose of administration of the patient to be administered. Although actual examples are given below, it goes without saying that the practice of the present invention is not restricted to these examples.

<Example 1>
In the present invention, the main preparations containing lactoferrin are oral preparations such as granules, tablets, capsules and the like. A general point to be noted in the formulation is that lactoferrin is susceptible to heat denaturation, and is particularly unstable in the presence of moisture. In addition, when glucose, lactose, etc. coexist in the preparation, an aminocarbonyl reaction occurs and irreversibly becomes an advanced protein glycation end product (AGE) and browns. Therefore, reducing sugar may be mixed into the preparation. Should be avoided as much as possible. On the other hand, lactoferrin is easily hydrolyzed by pepsin in the presence of gastric acid, so in any case, such as granules, tablets, capsules, etc., avoid hydrolysis in the stomach and denature and down to the small intestine where the lactoferrin receptor is present. It is essential to have an enteric preparation that can be reached without undergoing hydrolysis. In addition, since the lactoferrin powder is produced by freeze drying or spray drying, the specific gravity per unit volume is very light. Therefore, it is necessary to add an appropriate amount of cellulose and its derivatives, starch and its derivatives as excipients, disintegrants, and binders. Since all are enteric preparations, a usage instruction “do not chew or chew in the mouth, just as it is” is essential.

<Example 2>
Lactoferrin freeze-dried powder or spray-dried powder has a very low specific gravity per unit volume, and the powdered powder adheres to the surface of the punch during tableting, causing sticking and binding, making it difficult to compress directly into tablets. . Moreover, since it is unstable at moisture and high temperature, it is desirable to formulate in a dry state. Therefore, lactoferrin is mixed with active ingredients, excipients, binders, and disintegrants used in alternative medicine, and the mixture is pressed with a slag machine to form a thin, flat and large disk that is crushed and filtered to a certain size. Align the pods of Sano. The granules can be covered with an enteric coating, and a certain amount can be filled into a hard capsule to produce a product. In addition, in the case of commercialization as a tablet, a lubricant can be added to the granule and keyed, and the tablet can be covered with an enteric film to be commercialized.

<Example 3>
1 part of bovine lactoferrin, 10 parts of powder obtained by ultrafiltration of defatted colostrum (immunoglobulin content 60%) and 10 parts of microcrystalline cellulose and 0.5 part of sodium salt of carboxymethylcellulose are mixed. 150 mg of powder is filled into a hard capsule, and a solution such as cellulose acetate phthalate, hydroxypropylmethylcellulose, shellac, zein, etc. that forms an enteric coating is sprayed to form an enteric coating on the capsule surface to produce a product.

<Example 4>
1 part each of docosahexaenoic acid ethyl ester and eicosapentadecanoic acid ethyl ester are added to 20 parts of lactoferrin and mixed to soak the liquid ω-3 fatty acid ester into the lactoferrin powder. 150 mg of the powdery mixture is filled into an enteric hard capsule, and the fitting part is coated with an enteric coating and sealed to produce a product.

<Example 5>
A 0.7 mm thick membrane manufactured by heating 10 mg of a tablet containing 50 mg of lactoferrin, 100 mg of hot water extract of Agaricus and 25 mg of powdered propolis to 10 parts of gelatin and 20 parts of ribonucleic acid sodium and heating. After forming a jacket by a flat plate method, an enteric preparation was produced by drying.

<Example 6>
Enter a coating machine containing lactoferrin 50mg, ginkgo biloba extract 50mg in diameter 8mm diameter and 180mg weight, enteric coating consisting of 9% carboxymethyl ethyl cellulose, 1% glycerin fatty acid ester, 45% ethanol, 45% methylene chloride The liquid was sprayed, and a 10% enteric coating was applied to the tablet by weight to give a product.

<Example 7>
One tablet containing 100 mg lactoferrin, 0.3 mg zinc gluconate, 50 mg fucoidan, 10 mm in diameter and 180 mg in weight is put into a coating machine, protein obtained from corn kernels, 8 parts zein, 2 parts glycerin 70% ethanol The liquid dissolved in 150 parts was sprayed by the calculated amount to obtain a tablet coated with 10% by weight of the tablet.

<Example 8>
One tablet containing 50 mg lactoferrin in a diameter of 8 mm and a weight of 180 mg is put into a coating machine, NHC-60N), and 30 parts of shellac and 7 parts of castor oil are dissolved in 63 parts of isopropanol and sprayed in a calculated amount. Tablets with a coating of 10% by weight of the tablet were produced.
[The invention's effect]

  The effects of the present invention are as follows. (1) The ability to enhance the therapeutic effect of lactoferrin for intractable diseases, (2) The complexity of ingesting several types of drugs or health supplements by mixing and formulating lactoferrin and active ingredients used in alternative medicine Be free.

Claims (20)

  Lactoferrin and vitamin C, vitamin E, folic acid, vitamin D, organic and inorganic calcium salts, glucosamine sulfate, chondroitin sulfate, γ-linolenic acid, eicosapentadecanoic acid, docosahexaenoic acid and other omega-3 essential fatty acids, first A novel pharmaceutical composition for treating arthritis and a processed food comprising one or more selected from protein concentrates of milk powder and colostrum powder, chili extract or capsaicin, ginger extract and the like.   Containing one or two or more selected from lactoferrin and vitamin C, ω-3 essential fatty acids such as γ-linolenic acid, eicosapentadecanoic acid, docosahexaenoic acid, flavonoids, glycyrrhizin, licorice extract and the like A novel pharmaceutical composition for treating allergy and processed food. A novel pharmaceutical composition for treating anemia and processed food comprising one or more selected from lactoferrin, vitamin B ₁₂ , iron agents such as folic acid, iron gluconate, and heme iron. Lactoferrin and vitamin B _12, vitamin E, L-carnitine, phosphatidylserine, vinpocetine, New Alzheimer's disease and memory disorders treatment, characterized in that it contains one or more two selected from Ginkgo biloba extract so Pharmaceutical composition and processed food.   A novel pharmaceutical composition for bronchitis treatment and processed food comprising lactoferrin and a zinc compound such as zinc gluconate.   Lactoferrin and calcium, folic acid, selenium, vitamin C, vitamin E, carotenoids, isoflavones, lactic acid bacteria and bifidobacteria, grape seed extract, green tea extract, inositol-hexaphosphate, peptidoglycan and glycan extracted from basidiomycetes, A novel cancer therapeutic pharmaceutical composition and processed food comprising one or more selected from propolis and the like. Lactoferrin and nicotinic acid, vitamin B ₆ vitamin B ₁₂ , vitamin E, folic acid, koji mold, γ-linolenic acid, eicosapentadecanoic acid, omega-3 fatty acids such as docosahexaenoic acid, plant sterol, green tea and its extract grape A novel pharmaceutical composition for treating hypercholesterolemia and arteriosclerosis, comprising one or more selected from seed extract, garlic and its extract, lysozyme, lactalbumin, whey protein, and the like, and processed food. A novel chronic containing one or more selected from lactoferrin and vitamin B group complex, magnesium salt, calcium salt, carnitine, coenzyme Q ₁₀ , sorghum extract, ginseng and its extract, etc. Pharmaceutical compositions for treating fatigue syndrome and processed foods.   A novel pharmaceutical composition for treating constipation and a processed food comprising one or more selected from lactoferrin, kelp, senna and extracts thereof.   A novel pharmaceutical composition for treating depression and a processed food comprising one or more selected from lactoferrin and a vitamin B group complex, phenylalanine, S-adenosylmethionine, ginkgo biloba extract and the like.   A novel pharmaceutical composition for treating colds, comprising one or more selected from lactoferrin and vitamin C, zinc compounds such as zinc gluconate, vitamin A, egg white lysozyme, garlic and extracts thereof, and the like, and processed food.   Lactoferrin and fish oil, linseed oil and γ-3 linolenic acid, eicosapentadecanoic acid, docosahexaenoic acid and other omega-3 fatty acids, quercetin, grape seed extract, ginkgo biloba extract, licorice extract containing glycyrrhizin A novel dermatitis and eczema pharmaceutical composition and processed food, characterized by containing one or more selected from the above.   Lactoferrin and calcium salts, potassium salts, vitamin C, vitamin E, fish oil, linseed oil and omega-3 fatty acids such as γ-linolenic acid, eicosapentadecanoic acid, docosahexaenoic acid, garlic and extracts thereof, etc. A novel pharmaceutical composition for treating hypertension and a processed food comprising one or more selected from the group consisting of:   One selected from lactoferrin and zinc compounds such as folic acid and zinc gluconate, lactic acid bacteria and bifidobacteria, γ-linolenic acid, eicosapentadecanoic acid, docosahexaenoic acid and other essential omega-3 fatty acids, licorice extract, etc. And a novel pharmaceutical composition for treating inflammatory bowel disease and a processed food, characterized by containing two or more. A novel pharmaceutical composition for treating liver disease and processed food, comprising one or more selected from lactoferrin and a vitamin B group complex, coenzyme Q ₁₀ , digestive enzymes, licorice extract and the like.   A novel pharmaceutical composition for treating stomatitis and processed food, wherein lactoferrin contains one or more selected from vitamin B complex, vitamin C, zinc compounds such as zinc gluconate, licorice extract, etc. . Immunoglobulin concentrate of lactoferrin and bovine colostrum and bovine colostrum, egg white lysozyme, calcium salts, vitamin D, vitamin C, fluorine compounds, flavonoids, that it contains one or two or more selected from coenzyme Q _10, etc. A novel pharmaceutical composition for treating dental caries and periodontal disease and processed food.   A novel pharmaceutical composition for the treatment of urinary tract infections, comprising one or more selected from lactoferrin and vitamin C, bovine colostrum, bovine colostrum immunoglobulin concentrate, and cranberry extract Food.   A novel anti-obesity pharmaceutical comprising one or more selected from lactoferrin and chromium compounds, pepper tincture, capsaicin, raspberry alcoholic extract, carnitine, 5-hydroxytryptamine, konjac and glucomannan Compositions as well as processed foods.   A novel pharmaceutical composition for treating peptic ulcer, comprising one or more selected from lactoferrin and vitamin C, iron agents such as iron gluconate, lactic acid bacteria and bifidobacteria, licorice and extracts thereof As well as processed foods.